Sept 17 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening 34
points lower at 6,044 on Thursday, according to financial bookmakers.
* ASTRAZENECA: The adverse events that led to a pause in trials evaluating
AstraZeneca Plc's AZN.L COVID-19 vaccine candidate may not have been associated
with the vaccine itself, according to a document outlining participant
information that was posted online by the Oxford University. * BOE: The Bank of England is expected to signal on Thursday that it is
getting ready to pump yet more stimulus into Britain's economy as it heads for a
jump in unemployment and a possible Brexit shock. * ROLLS-ROYCE: Britain's Rolls-Royce RR.L said on Wednesday it continued
to review funding options, including debt and equity, to boost its balance
sheet. * NATWEST: NatWest NWG.L said late on Wednesday that its digital banking
services were back up after experiencing an outage. * GOLD: Gold prices fell more than 1%, as the dollar climbed after the U.S.
Federal Reserve painted a favourable economic recovery picture but stopped short
of offering concrete signals on further stimulus. * OIL: Oil prices fell, after rising in the two previous sessions, as
concerns about weak fuel demand re-emerged after production platforms in the
southeastern United States took steps to resume output following Hurricane
Sally's passage. * EX-DIVS: Intertek Group ITRK.L will trade without entitlement to its
latest dividend pay-out on Thursday, trimming 0.2 points off the FTSE 100
according to Reuters calculations. .L/XD
* London-listed stocks slipped on Wednesday as the fraught trade talks
between Britain and the European Union remained in focus. UK CORPORATE DIARY:
Clinigen Group CLINC.L FY results
Next Plc NXT.L HY results
Spire Healthcare SPI.L HY results
IG Group IGG.L Q1 trading update
Kier Group KIE.L FY results
Hilton Food Group HFG.L HY results
Playtech PTEC.L HY results
* For more on the factors affecting European stocks, please click on:
LIVE/
TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB